AUS
NZ
UK
CA
USA
IND
Highlights
- Dimerix granted Amicus Therapeutics exclusive U.S. rights to kidney drug DMX-200 in a deal worth up to USD 590 million (~AUD 940 million).
- The FDA has confirmed proteinuria reduction as the primary endpoint for DMX-200's regulatory pathway.
- DXB shares surged 41.67% on 1 May 2025; up 73.53% over the past year and 40.48% in the last month.
Shares of Dimerix Limited (ASX:DXB), a clinical-stage biopharmaceutical company, have seen a sharp rise over the past year, gaining 73.53%. In just the past month, the stock has surged by 40.48%, with a standout performance on 1 May, when it jumped 41.67% in a single session.
The rally was triggered by news of a strategic licensing agreement with Amicus Therapeutics (Nasdaq:FOLD), a US-based biotechnology firm. Under the deal, Amicus has secured exclusive rights to commercialise DMX-200—Dimerix’s late-stage kidney drug candidate—in the United States. The agreement is valued at up to USD 590 million (approximately AUD 940 million).
The licensing agreement follows Dimerix’s successful Type C meeting with the U.S. Food and Drug Administration (FDA) in March 2025. During the meeting, Dimerix and the FDA aligned on proteinuria reduction as the primary endpoint for regulatory approval.
Recent developments
In April 2025, DXB reported key milestones in its March quarter update. These included the FDA's confirmation of proteinuria as a clinical endpoint for DMX-200. The company also entered a licensing agreement with Fuso Pharmaceutical for the Japanese market, potentially worth up to AUD 107 million. At quarter-end, DXB held a cash position of AUD 17 million and continued advancing its pivotal ACTION3 Phase 3 clinical trial.
Recent financial performance update
In the half-year ended 31 December 2024 (1HFY25), DXB’s revenue jumped 113% YoY to AUD 0.48 million, primarily driven by license income. License revenue increased by 116% YoY to AUD 0.29 million. Losses widened to AUD 12.91 million due to ongoing R&D investment into the ACTION3 trial and other operational costs.
Outlook
Looking ahead, DXB’s outlook is underpinned by its collaboration with Amicus, which accelerates DMX-200’s U.S. commercial path. The company could receive up to USD 560 million in milestone payments and earn royalties from future U.S. sales. Interim ACTION3 trial data remains encouraging, with DMX-200 outperforming placebo in reducing proteinuria. DXB will continue funding the trial while Amicus manages U.S. regulatory submissions and commercialisation efforts.
Share performance of DXB
DXB shares closed 0.84% lower at AUD 0.59 per share on 14 May 2025. 52-week high of DXB is AUD 0.785, recorded on 5 May 2025 and 52-week low is AUD 0.30, recorded on 23 December 2024.
Support and Resistance Summary
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 14 May 2025. The reference data in this report has been partly sourced from EODHD/Others.
Technical Indicators Defined:
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.
